Antag Therapeutics ApS
Private limited companyCVR 38402056København NActive
Antag Therapeutics ApS is a private limited company, based in København N, active in manufacture of pharmaceutical preparations, founded in 2017. The company made a loss in both 2024 and 2025, most recently DKK 201m. Equity fell to DKK 235k in 2025. 8 other companies in the database are registered at the same address.
Key figures · financial year 2025
Gross profit−DKK 191.6m−526.2% vs. 2024
Net profit−DKK 201m−523% vs. 2024
EquityDKK 235k−99.9% vs. 2024
Employees9latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss grew: from DKK 32.3m to DKK 201m (2024 → 2025).
- Equity fell 100% (2024 → 2025), to DKK 235k.
Employees
- 2 more employees than a year earlier: 9 (07/2026) against 7 (07/2025).
Management and owners, last 24 months
- New in management: Alexander Volker Wilhelm Mayweg (board member, 05/11/2024), Amit Kantilal Shah (board member, 05/11/2024) and Philip Just Larsen (ceo, 31/03/2026) (+7).
- Stepped down: Alexander Hovard Sparre-Ulrich (ceo, 06/01/2025), Jens Juul Holst (board member, 05/11/2024) and Pieter Jeroen Bakker (board member, 05/11/2024) (+5).
- New owners registered: Novo Holdings A/S (08/04/2026), SR One Capital Fund II Aggregator, LP (08/04/2026) and Versant Venture Capital VII, L.P. (08/04/2026) (+7).
- No longer registered as owner: Sparre-Ulrich Holding ApS (09/01/2026), Novo Holdings A/S (07/04/2026) and Broadview Ventures I LLC (08/04/2026) (+7).
Registrations, last 24 months
- 08/04/2026: Share capital changed from 376,857 DKK to 487,848 DKK
- 09/01/2026: Share capital changed from 339,860 DKK to 376,857 DKK
- 05/11/2024: Share capital changed from 135,301 DKK to 339,860 DKK
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | −10,925 | −13,086 | −9,904 | −13,708 | −30,596 | −191,588 | −526.2% |
| Operating profit (EBIT) | −14,645 | −15,772 | −11,440 | – | −33,352 | −206,888 | −520.3% |
| Profit before tax | −14,973 | −17,459 | −11,997 | −16,971 | −37,405 | −206,500 | −452.1% |
| Net profit | −12,353 | −14,863 | −9,784 | −13,811 | −32,265 | −201,000 | −523% |
| Total assets | 15,721 | 20,671 | 17,564 | 23,970 | 225,361 | 28,033 | −87.6% |
| Equity | −9,769 | 10,858 | 4,639 | −9,173 | 201,235 | 235 | −99.9% |
| Liabilities | 25,490 | 9,813 | 12,925 | – | 24,126 | 27,797 | +15.2% |
| Cash and cash equivalents | 12,600 | 17,541 | 12,996 | 19,406 | 213,416 | 20,606 | −90.3% |
| Average number of employees | 7 | 6 | 2 | 2 | 2 | 10 | +400% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 6 years in a row
Net result has been negative in 2020–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
Equity fell sharply
Equity fell 100% from 2024 to 2025 (DKK 201.2m to DKK 235k).
How is this calculated?
Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.
Low equity ratio
Equity makes up 1% of total assets in 2025.
How is this calculated?
Equity ÷ total assets is below 10% in the latest annual report. Banks, insurers and some industries naturally have a low ratio.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 12/06/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 02/07/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 01/07/2024 | The company | PDF not statedXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 19/06/2023 | The company | PDFXBRL |
| 2021 | 01/01/2021 – 31/12/2021 | 05/07/2022 | The company | PDFXBRL |
| 2020 | 01/01/2020 – 31/12/2020 | 16/07/2021 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
59 companies in the databaseComparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.
Gross profit−DKK 191.6mNo. 56 of 57
Better than 2% of the companies in the industry
EquityDKK 235kNo. 44 of 59
Better than 26% of the companies in the industry
Number of employees9No. 29 of 59
Better than 52% of the companies in the industry
Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 69,740of 69,742 Better than 0% | No. 49,271of 69,964 Better than 30% |
| Same industry and fewer than 20 employees37 companies in the comparison | No. 36of 36 Better than 0% | No. 25of 37 Better than 33% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 33,585of 33,588 Better than 0% | No. 23,460of 33,687 Better than 30% |
| All companies of type ApS66,508 companies in the comparison | No. 66,379of 66,379 Better than 0% | No. 45,305of 66,505 Better than 32% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Manufacture of pharmaceutical preparationsGross profit
- Antag Therapeutics ApS−DKK 191.6m
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
Net profit
- Antag Therapeutics ApS−DKK 201m
- Novo Nordisk A/SDKK 102.4bn
- H. Lundbeck A/SDKK 3.2bn
Equity
- Antag Therapeutics ApSDKK 235k
- Novo Nordisk A/SDKK 194bn
- H. Lundbeck A/SDKK 24.9bn
Employees
- Antag Therapeutics ApS9
- Novo Nordisk A/S27,279
- H. Lundbeck A/S2,261
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
- Novo Holdings A/S20%
- SR One Capital Fund II Aggregator, LP5%
- Versant Venture Capital VII, L.P.25%
- Dawn Holdco SCSp10%
Antag Therapeutics ApS
Management
7 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Philip Just Larsen | CEO | 31/03/2026 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Philip Just Larsen | Board member | 28/09/2018 |
| Mark Currie | Board member | 01/06/2023 |
| Alexander Volker Wilhelm Mayweg | Board member | 05/11/2024 |
| Amit Kantilal Shah | Board member | 05/11/2024 |
| Jørgen Søberg Petersen | Board member | 08/06/2026 |
| Keith Richard Leonard Jr | Chair of the board | 08/06/2026 |
- Founders
- Laustsen Ventures ApS, Mette Marie Rosenkilde, Healthcare Ventures ApS, Lark Holding ApS, Sparre-Ulrich Holding ApS, Maria Buur Nordskov Gabe, Jens Juul Holst
Former management (14)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Alexander Hovard Sparre-Ulrich | CEO | 08/02/2017 | 06/01/2025 |
| Kirsten Aarup Drejer | Chair of the board | 31/05/2017 | 01/06/2023 |
| Anker Gunvald Lundemose | Board member | 31/05/2017 | 31/12/2020 |
| Emmanuelle Coutanceau | Board member | 31/05/2017 | 02/09/2020 |
| Jens Juul Holst | Board member | 31/05/2017 | 05/11/2024 |
| Pieter Jeroen Bakker | Board member | 11/03/2020 | 05/11/2024 |
| Thomas Edward Needham Jr. | Board member | 11/03/2020 | 12/09/2023 |
| Christine Theresa Fischette | Board member | 28/06/2021 | 01/06/2023 |
| Jayson Dallas | Board member | 01/06/2023 | 13/09/2023 |
| Jørgen Søberg Petersen | Board member | 05/11/2024 | 07/04/2026 |
| Alexander Hovard Sparre-Ulrich | Board member | 05/11/2024 | 28/01/2025 |
| Jörg Möller | CEO | 06/01/2025 | 31/03/2026 |
| Jörg Möller | Board member | 28/01/2025 | 31/03/2026 |
| Jørgen Søberg Petersen | Chair of the board | 08/04/2026 | 07/06/2026 |
Signing rule: Selskabet tegnes af to medlemmer af bestyrelsen i forening, af en direktør i forening med bestyrelsesformanden, eller af den samlede bestyrelse.
Address and production units
1 active production unitsOle Maaløes Vej 3
2200 København N
København Municipality · Postcode 2200
Other companies at the address (8)
- BII Holdings A/SOther financial service activities n.e.c.
- Skape Bio ApSResearch and experimental development on natural sciences and engineering
- Agrobiomics ApSResearch and experimental development on natural sciences and engineering
- Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
- BioColor ApSResearch and experimental development on natural sciences and engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Antag Therapeutics ApS | Ole Maaløes Vej 3, 2200 København N | 10 | 1022172227 |
Purpose
Selskabets formål er forskning og udvikling af lægemidler samt dermed beslægtet virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
98 registered events222017
22018
02019
42020
152021
22022
92023
112024
52025
282026
202628 changesaccounts 1 · management 8 · capital 2 · ownership 17
- AccountsAnnual report for 2025 published
- ManagementKeith Richard Leonard Jr appointed chair of the board
- ManagementJørgen Søberg Petersen appointed board member
- ManagementJørgen Søberg Petersen stepped down as chair of the board
- CapitalShare capital changed from 376,857 DKK to 487,848 DKK
- ManagementJørgen Søberg Petersen appointed chair of the board
- OwnershipSR One Capital Fund II Aggregator, LP registered as owner (5%)
- OwnershipDawn Holdco SCSp registered as owner (10%)
- OwnershipVersant Venture Capital VII, L.P. registered as owner (25%)
- OwnershipNovo Holdings A/S registered as owner (20%)
- OwnershipBroadview Ventures I LLC is no longer registered as owner
- ManagementJørgen Søberg Petersen stepped down as board member
- OwnershipVersant Venture Capital VII, L.P. is no longer registered as owner
- OwnershipDawn Holdco SCSp is no longer registered as owner
- OwnershipSR One Capital Fund II Aggregator, LP is no longer registered as owner
- OwnershipNovo Holdings A/S is no longer registered as owner
- ManagementPhilip Just Larsen appointed ceo
- ManagementJörg Möller stepped down as board member
- ManagementJörg Möller stepped down as ceo
- CapitalShare capital changed from 339,860 DKK to 376,857 DKK
- OwnershipVersant Venture Capital VII, L.P. registered as owner (15%)
- OwnershipDawn Holdco SCSp registered as owner (10%)
- OwnershipSR One Capital Fund II Aggregator, LP registered as owner (10%)
- OwnershipDanmarks Eksport- og Investeringsfond is no longer registered as owner
- OwnershipSparre-Ulrich Holding ApS is no longer registered as owner
- OwnershipSR One Capital Fund II Aggregator, LP is no longer registered as owner
- OwnershipDawn Holdco SCSp is no longer registered as owner
- OwnershipVersant Venture Capital VII, L.P. is no longer registered as owner
20255 changesaccounts 1 · management 4
- AccountsAnnual report for 2024 published
- ManagementJörg Möller appointed board member
- ManagementAlexander Hovard Sparre-Ulrich stepped down as board member
- ManagementJörg Möller appointed ceo
- ManagementAlexander Hovard Sparre-Ulrich stepped down as ceo
202411 changescapital 1 · management 6 · ownership 3 · accounts 1
- CapitalShare capital changed from 135,301 DKK to 339,860 DKK
- ManagementAlexander Hovard Sparre-Ulrich appointed board member
- ManagementJørgen Søberg Petersen appointed board member
- ManagementAlexander Volker Wilhelm Mayweg appointed board member
- ManagementAmit Kantilal Shah appointed board member
- ManagementPieter Jeroen Bakker stepped down as board member
- ManagementJens Juul Holst stepped down as board member
- OwnershipSR One Capital Fund II Aggregator, LP registered as owner (5%)
- OwnershipDawn Holdco SCSp registered as owner (5%)
- OwnershipVersant Venture Capital VII, L.P. registered as owner (20%)
- AccountsAnnual report for 2023 published
20239 changesmanagement 6 · accounts 1 · ownership 2
- ManagementJayson Dallas stepped down as board member
- ManagementThomas Edward Needham Jr. stepped down as board member
- AccountsAnnual report for 2022 published
- ManagementJayson Dallas appointed board member
- ManagementMark Currie appointed board member
- ManagementChristine Theresa Fischette stepped down as board member
- ManagementKirsten Aarup Drejer stepped down as chair of the board
- OwnershipDanmarks Eksport- og Investeringsfond registered as owner (5%)
- OwnershipVÆKSTFONDEN is no longer registered as owner
20222 changesaccounts 1 · capital 1
- AccountsAnnual report for 2021 published
- CapitalShare capital changed from 130,639 DKK to 135,301 DKK
202115 changescapital 4 · ownership 9 · accounts 1 · management 1
- CapitalShare capital changed from 129,124 DKK to 130,639 DKK
- OwnershipBroadview Ventures I LLC registered as owner (5%)
- OwnershipBroadview Ventures I LLC is no longer registered as owner
- CapitalShare capital changed from 124,992 DKK to 129,124 DKK
- OwnershipVÆKSTFONDEN registered as owner (5%)
- OwnershipLark Holding ApS is no longer registered as owner
- OwnershipMette Marie Rosenkilde is no longer registered as owner
- OwnershipJens Juul Holst is no longer registered as owner
- AccountsAnnual report for 2020 published
- CapitalShare capital changed from 80,881 DKK to 124,992 DKK
- ManagementChristine Theresa Fischette appointed board member
- OwnershipBroadview Ventures I LLC registered as owner (10%)
- CapitalShare capital changed from 76,060 DKK to 80,881 DKK
- OwnershipNovo Holdings A/S registered as owner (25%)
- OwnershipNovo Holdings A/S is no longer registered as owner
20204 changesmanagement 4
- ManagementAnker Gunvald Lundemose stepped down as board member
- ManagementEmmanuelle Coutanceau stepped down as board member
- ManagementPieter Jeroen Bakker appointed board member
- ManagementThomas Edward Needham Jr. appointed board member
20182 changescapital 1 · management 1
- CapitalShare capital changed from 64,000 DKK to 76,060 DKK
- ManagementPhilip Just Larsen appointed board member
201722 changesaddress 1 · management 5 · name 1 · capital 1 · ownership 13 · founded 1
- AddressMoved to Ole Maaløes Vej 3, 2200 København N
- ManagementEmmanuelle Coutanceau appointed board member
- ManagementJens Juul Holst appointed board member
- ManagementAnker Gunvald Lundemose appointed board member
- ManagementKirsten Aarup Drejer appointed chair of the board
- NameName changed from Antag Therapeutics IVS to Antag Therapeutics ApS
- CapitalShare capital changed from 10,000 DKK to 64,000 DKK
- OwnershipLark Holding ApS registered as owner (5%)
- OwnershipNovo Holdings A/S registered as owner (33.33%)
- OwnershipMette Marie Rosenkilde registered as owner (5%)
- OwnershipJens Juul Holst registered as owner (5%)
- OwnershipSparre-Ulrich Holding ApS registered as owner (10%)
- OwnershipLark Holding ApS is no longer registered as owner
- OwnershipJens Juul Holst is no longer registered as owner
- OwnershipSparre-Ulrich Holding ApS is no longer registered as owner
- OwnershipMette Marie Rosenkilde is no longer registered as owner
- FoundedRegistered as Antag Therapeutics IVS
- ManagementAlexander Hovard Sparre-Ulrich appointed ceo
- OwnershipLark Holding ApS registered as owner (15%)
- OwnershipJens Juul Holst registered as owner (15%)
- OwnershipSparre-Ulrich Holding ApS registered as owner (33.33%)
- OwnershipMette Marie Rosenkilde registered as owner (15%)
Related companies
Same industry in København
- H. Lundbeck A/S2,261 employees
- AJ Vaccines A/S499 employees
- Tetra Pharm Technologies ApS39 employees
- Motilitycount ApS29 employees
- Freya Biosciences ApS18 employees
- Zerion Pharma A/S15 employees
Same people in management
- International N&H Denmark ApSvia Kirsten Aarup Drejer
- Zealand Pharma A/Svia Jørgen Søberg Petersen
- Servier Symphogen A/Svia Anker Gunvald Lundemose
- Bioneer A/Svia Kirsten Aarup Drejer
- Adcendo ApSvia Pieter Jeroen Bakker
- Hemab ApSvia Jørgen Søberg Petersen
Largest in the industry
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Leo Pharma A/SDKK 8.2bn
- Alk-abelló A/SDKK 4.2bn
- Bavarian Nordic A/SDKK 3bn
- Pharmacosmos A/SDKK 1.6bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.